Clinical manifestations of cryptococcus gattii infection: Determinants of neurological sequelae and death

Clinical Infectious Diseases

Volumn 55, Issue 6, 2012, Pages 789-798

  Chen, Sharon C A ^a,b,c   Slavin, Monica A ^e   Heath, Christopher H ^g   Geoffrey Playford, E ^j   Byth, Karen ^c   Marriott, Deborah ^d   Kidd, Sarah E ^k   Bak, Narin ^l   Currie, Bart ^m   Hajkowicz, Krispin ^m   Korman, Tony M ^f   McBride, William J H ⁿ   Meyer, Wieland ^a,b   Murray, Ronan ^h,i   Sorrell, Tania C ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h PATHWEST LABORATORY MEDICINE   (Australia)

ⁱ SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^j PRINCESS ALEXANDRA HOSPITAL   (Australia)

^k WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^l ROYAL ADELAIDE HOSPITAL   (Australia)

^m ROYAL DARWIN HOSPITAL   (Australia)

ⁿ JAMES COOK UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CORTICOSTEROID; CRYPTOCOCCAL ANTIGEN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; AUSTRALIA; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID CULTURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS GATTII INFECTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; FUNGUS CULTURE; GEOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRACRANIAL HYPERTENSION; LABORATORY TEST; LUNG; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SYMPTOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CEREBROSPINAL FLUID; CEREBRUM; CRYPTOCOCCUS GATTII; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SPINAL PUNCTURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865468437     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis529     Document Type: Article

References (34)

1. Pukkila-Worley R, Mylonakis E. Epidemiology and management of cryptococcocal meningitis: developments and challenges. Expert Opin Pharmacother 2008; 9:551-60. (Pubitemid 351425383)
2. Heitman J, Kozel T, Kwon-Chung KJ, Perfect JR, Casadevall A. Cryptococcus from human pathogen to model yeast. Washington, DC: ASM Press, 2011.
3. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611-6.
4. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host-and varietydependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000; 31:499-508. (Pubitemid 32289583)
5. Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol 2001; 39:155-68. (Pubitemid 32377312)
6. MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007; 13:42-50. (Pubitemid 46057836)
7. Galanis E, MacDougall L, Kidd S, Morshed MG, the British Columbia Cryptococcus working group. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16:251-7. Erratum: 16:750.
8. Datta K, Bartlett KH, Baer R, et al. Spread of Cryptococcus gattii into the Pacific Northwest region of the United States. Emerg Infect Dis 2009; 15:1185-91.
9. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia. Emerg Infect Dis 2011; 17:193-9.
10. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1185-95.
11. Marr KA. Cryptococcus gattii: the tip of the iceberg. Clin Infect Dis 2011; 53:1196-8.
12. Galanis E, Hoang L, Kibsey P, Morshed M, Phillips P. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: lessons learned from British Columbia. Can J Dis Med Microbiol 2009; 20:23-8.
13. Jenny A, Pandithage K, Fisher DA, Currie BJ. Cryptococcus infection in tropical Australia. J Clin Microbiol 2004; 42:3865-8. (Pubitemid 39045733)
14. International statistical classification of disease and related health problems, 10th revision, Australian Modification (ICD-10-AM). Sydney, Australia: University of Sydney, 1998.
15. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, the French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D Study. PLoS Medicine 2007; 4:e21.
16. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322.
17. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639-46.
18. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F, the French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIVassociated cryptococcosis in France. AIDS 2005; 19:1043-9. (Pubitemid 40961144)
19. Smith DK, Neal JJ, Holmberg SD. Unexplained opportunistic infections and CD4+ T-lymphopenia without HIV infection. An investigation of cases in the United States. the Centers for Disease Control idiopathic CD4+ T-lymphocytopenia task force. N Engl J Med 1993; 328:373-9. (Pubitemid 23042284)
20. Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, Barron EJ, Jorgensen JH, Landry MLPfaller MA, eds. Manual of clinical microbiology. Washington, DC: ASM Press, 2007; 7:62-88.
21. Australian Bureau of Statistics. Census of Population and Housing, Australia. November 2006. Available at: http://www.abs/gov/au/. Accessed 1 September 2011.
22. Australian Bureau of Statistics. Tobacco smoking in Australia: a snapshot, 2004-2005. 15 September 2006. Available at: http://www.abs/gov/au/. Accessed 1 September 2011.
23. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcus in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:90-9.
24. Australian Bureau of Statistics. Births, Australia, 2010. 25 October 2011. Available at: http://www.abs/gov/au/. Accessed 1 September 2011.
25. Australian Bureau of Statistics. Diabetes in Australia: a snapshot, 2004-05. August 2006. Available at: http://www.abs/gov/au/. Accessed 1 September 2011.
26. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28-34.
27. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990; 28:1642-44. (Pubitemid 20212901)
28. Zonios D, Falloon J, Huang C-Y, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphopenia. Medicine 2007; 86:78-92.
29. Hope W, Looke D. Sequential infection with Nocardia farcinica and Cryptococcus neoformans var. gattii in an immunocompetent host. J Infect 2003; 47:256-9. (Pubitemid 37168627)
30. Dyer J, Ketheesan N, Norton RE, Ashhurst-Smith CIJ, Keary P, La Brooy JT. Disseminated infection due to Nocardia transvalensis coincident with Cryptococcus neoformans variety gattii meningitis. Eur J Clin Microbiol Infect Dis 1999; 18:587-90. (Pubitemid 29531228)
31. Lalloo D, Fisher D, Naraqi S, et al. Cryptococcal meningitis (C. neoforamns var. gattii) leading to blindness in previously-healthy melanesian adults in Papua New Guinea. Q J Med 1994; 87:343-9.
32. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. the NIAID mycoses study group and AIDS cooperative treatment groups. Clin. Infect Dis 2000; 30:c47-54.
33. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviralnaïve or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80. (Pubitemid 46984619)
34. Bicanic T, Muzoora C, Brouwer A, et al. Independent association between rate of clearance of infection and clinical outcome of HIVassociated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702-9.